Format

Send to

Choose Destination
Nat Med. 2004 Feb;10(2):145-7. Epub 2004 Jan 25.

Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer.

Author information

1
Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA. cwillett@partners.org

Erratum in

  • Nat Med. 2004 Jun;10(6):649.

Abstract

The effects of vascular endothelial growth factor (VEGF) blockade on the vascular biology of human tumors are not known. Here we show here that a single infusion of the VEGF-specific antibody bevacizumab decreases tumor perfusion, vascular volume, microvascular density, interstitial fluid pressure and the number of viable, circulating endothelial and progenitor cells, and increases the fraction of vessels with pericyte coverage in rectal carcinoma patients. These data indicate that VEGF blockade has a direct and rapid antivascular effect in human tumors.

Comment in

PMID:
14745444
PMCID:
PMC2693485
DOI:
10.1038/nm988
[Indexed for MEDLINE]
Free PMC Article

Publication types, MeSH terms, Substances, Grant support

Publication types

MeSH terms

Substances

Grant support

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center